This is the first study to assess the effectiveness of four GLP‐1 receptor‐based agonists (tirzepatide, semaglutide, liraglutide, and dulaglutide) against another predominantly glucose‐lowering therapy and provide head‐to‐head analyses, demonstrating a reduction in incident AUDs in patients with type 2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.